This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 6, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that
Wei-Wu He, Ph.D has joined the Board of Directors as Executive Chairman and
Tak W. Mak, Ph.D has joined as a member of the Board of Directors.
Wei-Wu He is currently the CEO and Chairman of OriGene Technologies, Inc. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established in
Maryland since 2000. Dr. He was also one of the first few employees at Human Genome Sciences, Inc. and from 1993 to 1996 was a scientist at the company. Prior to that he was a Research Fellow at
Massachusetts General Hospital and Mayo Clinic. Dr. He has been involved in founding and funding over 20 biotech companies throughout his career. Dr. He received his Ph.D. from
Baylor College of Medicine and MBA from The Wharton School of
University of Pennsylvania. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents.
Tak W. Mak is currently the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a University Professor in the Department of Medical Biophysics and Department of Immunology, University of Toronto. He was trained at the
University of Wisconsin in Madison, the
University of Alberta and the Ontario Cancer Institute. He is best known as the leading scientist of the group that first cloned the genes of the human T cell antigen receptor. Dr. Mak is an Officer of the Order of
Canada, and has been elected a Foreign Associate of the National Academy of Sciences (
USA), a Foreign Associate of the American Academy of Arts and Sciences, as well as a Fellow of the Royal Society of
London (UK). He was recently awarded the Order of
Ontario and has won international recognition in the form of the Emil von Behring Prize, the King Faisal Prize for Medicine, the Gairdner Foundation International Award, the Sloan Prize of the General Motors Cancer Foundation, the Novartis Prize in Immunology and the Paul Ehrlich Prize and Ludwig Darmstaedter Prize of
Germany. Dr. Mak's held the position of VP of Research at Amgen, Inc. and was Director of the Amgen Institute in
Toronto from 1993-2002. His experience as a venture capitalist allows him to be an integral part of start-up companies.
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company's web site at
www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.